U.S. sales of Pfizer's Comirnaty shots have taken a nosedive since the Trump administration updated its immunization schedules last month and dropped the universal collective recommendations for COVID-19 vaccines.

The pharmaceutical company's revenues for the third quarter of 2025 are down 6% — amounting to a $1 billion drop — compared to the same stretch the previous year.

'CDC's 2022 blanket recommendation for perpetual COVID-19 boosters deterred health care providers from talking about the risks.'

Pfizer indicated in its latest earnings statement that "the operational decrease was primarily driven by a year-over-year decline in COVID-19 product revenues largely due to lower infection rates impacting Paxlovid demand as well as a narrower vaccine recommendation for COVID-19 in the U.

See Full Page